Esketamine and Short-Term Memory Impairment
Yes, esketamine causes short-term cognitive impairment including memory deficits immediately after administration, but these effects are transient and resolve within hours, with no evidence of long-term memory impairment when used at therapeutic doses for depression.
Acute Cognitive Effects
The FDA label for esketamine explicitly warns about short-term cognitive impairment 1. In healthy volunteers, a single dose caused measurable cognitive performance decline at 40 minutes post-dose, with subjects requiring greater effort to complete cognitive tests. However, cognitive performance returned to baseline by 2 hours post-dose 1.
A meta-analysis of ketamine/esketamine in healthy subjects found small-to-moderate impairments across all cognitive domains, with verbal learning and memory being most prominently affected 2. These deficits are dose-dependent and correlate with plasma levels, but are independent of the enantiomer type (racemic ketamine vs. esketamine) 2.
Clinical Context: Depression Treatment
The picture differs substantially in patients with treatment-resistant depression (TRD). Analysis of four Phase 3 esketamine trials (n=884 patients) found that cognitive performance either remained stable or slightly improved from baseline at Day 28 and throughout long-term maintenance treatment 3. This apparent paradox occurs because:
- Patients with TRD have baseline mild-to-moderate cognitive impairment in psychomotor function, attention, and memory
- The antidepressant effects of esketamine may offset any direct cognitive effects
- Therapeutic doses (28-84 mg intranasal) are substantially lower than doses causing significant impairment in experimental settings
A systematic review specifically examining neurocognitive effects in TRD patients found that esketamine does not exert significant deleterious neurocognitive effects in short or long term 4. One study reported impairment in processing speed and verbal memory, while five studies reported improvements in various cognitive domains 4.
Risk Mitigation Requirements
The FDA mandates specific safety protocols 1:
- 2-hour post-administration monitoring is required due to acute cognitive effects
- Patients must not drive or operate machinery until the next day after restful sleep
- Healthcare setting certification and supervision during administration are mandatory (REMS program)
- Blood pressure monitoring is required (cognitive effects coincide with peak cardiovascular effects at ~40 minutes)
Long-Term Safety
Long-term cognitive impairment has been reported with repeated ketamine misuse or abuse at high doses 1, 5. However, clinical trials up to 3 years duration using therapeutic esketamine doses showed stable cognitive function over time as measured by validated neuropsychological batteries 1, 3, 5.
The VA/DoD 2022 guidelines acknowledge these risks but recommend esketamine for TRD patients who have failed multiple antidepressant trials, noting that "the balance of consistent evidence of benefit weighed against the risks for adverse effects" supports its use 6.
Clinical Bottom Line
Expect transient memory and cognitive impairment for approximately 2 hours post-dose, which is why mandatory observation is required. This acute effect does not translate to long-term cognitive harm when esketamine is used at therapeutic doses under proper medical supervision. The cognitive profile in depressed patients may actually improve due to treatment of the underlying depression, which itself causes cognitive dysfunction.
Common pitfall: Confusing high-dose ketamine abuse data (which does cause lasting cognitive impairment) with therapeutic esketamine dosing. The doses used recreationally are substantially higher and more frequent than medical protocols 5, 7.